Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910029 | 0.86 | HTT (0.56) | CPS1HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL3902455 | 0.85 | HPGD (0.60) | HPGDALDH1A1LMNAKDM4EHSD17B10 | |
| SCHEMBL3900880 | 0.84 | CPS1 (0.62) | CPS1HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL3901483 | 0.83 | HPGD (0.55) | HPGDALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL29944001 | 0.82 | HPGD (0.68) | CPS1HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL6710672 | 0.82 | HPGD (0.68) | CPS1HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL29944466 | 0.82 | ALDH1A1 (0.76) | CPS1HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL3897794 | 0.81 | KMT2A (0.50) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL3895784 | 0.81 | HPGD (0.53) | HPGDALDH1A1LMNAGAATSHR | |
| SCHEMBL2835948 | 0.79 | PARP1 (0.55) | HPGDALDH1A1LMNAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-7550492-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1675837-A2 | BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005012275-A2 | BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | CCKBR, CCKAR, GIPR | CPS1 2839/4885HPGD 1693/4885ALDH1A1 3254/4885 |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | CCKBR, CCKAR, BRSK2 | CPS1 2744/4885HPGD 1467/4885ALDH1A1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.